Health Care [ 4/12 ] | Biotechnology [ 18/72 ]
NASDAQ | Common Stock
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States.
The company provides UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; and CIMERLI, a biosimilar to Lucentis, a biosimilar product interchangeable with Lucentis for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization in the United States.
It also offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis.
Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; and Shanghai Junshi Biosciences Co., Ltd. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012.
Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 9, 24 | -0.32 Increased by +57.33% | -0.24 Decreased by -33.33% |
| Mar 13, 24 | -0.62 Decreased by -3.33% | -0.12 Decreased by -416.67% |
| Nov 6, 23 | -0.41 Increased by +57.29% | -0.27 Decreased by -51.85% |
| Aug 2, 23 | -0.38 Increased by +19.15% | -0.48 Increased by +20.83% |
| May 8, 23 | -0.75 Increased by +25.00% | -0.57 Decreased by -31.58% |
| Mar 6, 23 | -0.60 Decreased by -30.43% | -0.84 Increased by +28.57% |
| Nov 8, 22 | -0.96 Decreased by -182.35% | -0.57 Decreased by -68.42% |
| Aug 4, 22 | -0.47 Decreased by -30.56% | -0.64 Increased by +26.56% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 74.57 M Increased by +64.16% | -39.64 M Increased by +57.31% | Decreased by -53.16% Increased by +73.99% |
| Jun 30, 23 | 58.72 M Decreased by -2.39% | -42.87 M Increased by +23.84% | Decreased by -73.01% Increased by +21.98% |
| Mar 31, 23 | 32.44 M Decreased by -46.04% | -74.78 M Increased by +32.78% | Decreased by -230.55% Decreased by -24.59% |
| Dec 31, 22 | 45.35 M Decreased by -38.19% | -66.25 M Decreased by -44.88% | Decreased by -146.07% Decreased by -134.39% |
| Sep 30, 22 | 45.42 M Decreased by -44.94% | -92.85 M Decreased by -141.00% | Decreased by -204.41% Decreased by -337.72% |
| Jun 30, 22 | 60.15 M Decreased by -31.37% | -56.29 M Decreased by -88.25% | Decreased by -93.58% Decreased by -174.29% |
| Mar 31, 22 | 60.12 M Decreased by -27.60% | -111.24 M Increased by +35.68% | Decreased by -185.05% Increased by +11.16% |
| Dec 31, 21 | 73.37 M Decreased by -33.55% | -45.73 M Decreased by -571.00% | Decreased by -62.32% Decreased by -808.83% |